Chemed Corporation (NYSE:CHE) Shares Sold by Allianz Asset Management GmbH

Allianz Asset Management GmbH trimmed its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 23.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 6,326 shares of the company's stock after selling 1,937 shares during the period. Allianz Asset Management GmbH's holdings in Chemed were worth $3,893,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Wealth Alliance LLC lifted its holdings in shares of Chemed by 5.4% during the first quarter. Wealth Alliance LLC now owns 589 shares of the company's stock valued at $363,000 after purchasing an additional 30 shares during the last quarter. Brogan Financial Inc. raised its holdings in Chemed by 7.3% in the 1st quarter. Brogan Financial Inc. now owns 426 shares of the company's stock worth $262,000 after acquiring an additional 29 shares during the last quarter. Segall Bryant & Hamill LLC raised its holdings in Chemed by 35.6% in the 1st quarter. Segall Bryant & Hamill LLC now owns 32,956 shares of the company's stock worth $20,278,000 after acquiring an additional 8,645 shares during the last quarter. Lord & Richards Wealth Management LLC raised its holdings in Chemed by 109.1% in the 1st quarter. Lord & Richards Wealth Management LLC now owns 2,032 shares of the company's stock worth $1,250,000 after acquiring an additional 1,060 shares during the last quarter. Finally, CWM LLC raised its holdings in Chemed by 9.4% in the 1st quarter. CWM LLC now owns 421 shares of the company's stock worth $259,000 after acquiring an additional 36 shares during the last quarter. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on CHE. Wall Street Zen downgraded shares of Chemed from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Oppenheimer cut their target price on shares of Chemed from $650.00 to $580.00 and set an "outperform" rating for the company in a research report on Thursday. Bank of America cut their target price on shares of Chemed from $708.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Jefferies Financial Group began coverage on shares of Chemed in a research report on Friday, July 25th. They issued a "hold" rating and a $500.00 target price for the company. Finally, Royal Bank Of Canada cut their target price on shares of Chemed from $640.00 to $589.00 and set an "outperform" rating for the company in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Chemed currently has a consensus rating of "Moderate Buy" and an average target price of $579.75.

Insider Buying and Selling at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 1,500 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $576.45, for a total value of $864,675.00. Following the sale, the chief executive officer owned 101,197 shares in the company, valued at $58,335,010.65. The trade was a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Spencer S. Lee sold 1,500 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $577.99, for a total transaction of $866,985.00. Following the completion of the sale, the executive vice president owned 14,627 shares in the company, valued at approximately $8,454,259.73. The trade was a 9.30% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,500 shares of company stock worth $2,598,450. Corporate insiders own 3.29% of the company's stock.

Chemed Stock Performance

Shares of CHE stock traded up $1.44 during mid-day trading on Friday, reaching $413.74. 71,034 shares of the company's stock traded hands, compared to its average volume of 134,010. Chemed Corporation has a 12 month low of $408.42 and a 12 month high of $623.60. The firm has a 50 day moving average price of $511.87 and a two-hundred day moving average price of $553.52. The firm has a market capitalization of $6.05 billion, a PE ratio of 21.25, a price-to-earnings-growth ratio of 2.02 and a beta of 0.50.

Chemed (NYSE:CHE - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing the consensus estimate of $6.02 by ($1.75). The firm had revenue of $618.80 million during the quarter, compared to the consensus estimate of $650.60 million. Chemed had a return on equity of 25.83% and a net margin of 11.56%. The company's quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the company posted $5.47 EPS. As a group, equities analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Thursday, May 29th were paid a $0.50 dividend. The ex-dividend date was Thursday, May 29th. This represents a $2.00 annualized dividend and a yield of 0.5%. Chemed's payout ratio is presently 9.74%.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.